



NORWAY

(12) Translation of
European patent specification

(11) NO/EP 3206686 B1

(19) NO
(51) Int Cl.
A61K 31/44 (2006.01)
A61K 31/404 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2020.02.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.10.09
(86)	European Application Nr.	15833863.2
(86)	European Filing Date	2015.08.20
(87)	The European Application's Publication Date	2017.08.23
(30)	Priority	2014.08.20, US, 201462039786 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA
(73)	Proprietor	Samumed, LLC, 9381 Judicial Drive Suite 160, San Diego, California 92121, USA
(72)	Inventor	HOOD, John, 5124 Seagrove Court, San Diego, California 92130, USA KC, Sunil Kumar, 10504 Clasico Court, San Diego, California 92127, USA KIBAR, Osman, Samumed, LLC9381 Judicial Drive, San Diego, California 92121, USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES
(56)	References Cited:	WO-A1-2013/113722, US-A- 5 420 273 US-A1- 2010 210 036, US-A1- 2014 005 228 WO-A2-2007/103584, US-A1- 2013 172 291 US-A1- 2012 046 320,US-A1- 2014 179 642 WO-A1-01/49291, WO-A2-2011/009826 US-A1- 2007 185 152, US-A1- 2003 087 922

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Kosmetisk fremgangsmåte for å forbedre det estetiske utseendet på huden til et individ, fremgangsmåten omfatter å administrere til individet en effektiv mengde av en forbindelse med formel **I**, eller et dermatologisk akseptabelt salt derav:

**I**

hvor:

ring A er et 7-12-leddet heteroaryl, under forutsetning av at et karbonatom på ringen festes til karbonylkarbonet;

ring B velges fra gruppen som består av fenyl og et 5-6-leddet heteroaryl, under forutsetning av at et karbonatom på ringen festes til karbonylkarbonet;

R^1 er en substituent festet til ring A og velges uavhengig ved hver forekomst fra gruppen som består av usubstituert $-C_{1-6}$ alkyl, $-C_{1-3}$ halogenalkyl, haloid, $-OR^3$, og CN;

R^2 er en substituent festet til ring B og velges uavhengig ved hver forekomst fra gruppen som består av usubstituert $-C_{1-6}$ alkyl, $-CH_2OH$, $-CH_2N(R^{3b})_2$, $-C_{1-3}$ halogenalkyl, haloid, $-OR^3$ og CN;


hver R^3 velges uavhengig fra gruppen som består av H, umettet $-C_{1-6}$ alkyl og $-C_{1-3}$ halogenalkyl;

hver R^{3b} velges uavhengig fra gruppen som består av H og umettet C_{1-3} alkyl;


hver n 0 til 10; og

hver m er 0 til 5.

2. Fremgangsmåten ifølge krav 1, hvor ring A velges fra gruppen som består av:



3. Fremgangsmåten ifølge et hvilket som helst av kravene 1-2, hvor ring A velges fra gruppen som består av:




4. Fremgangsmåten ifølge et hvilket som helst av kravene 1-3, hvor minst ett R^1 er haloid.


5. Fremgangsmåten ifølge et hvilket som helst av kravene 1-3, hvori n er 0.

6. Fremgangsmåten ifølge et hvilket som helst av kravene 1-5, hvori ring B er fenyl.

5 **7.** Fremgangsmåten ifølge et hvilket som helst av kravene 1-6, hvori




velges fra gruppen som består av




og

10 **8.** Fremgangsmåten ifølge et hvilket som helst av kravene 1-7, hvori



velges fra gruppen som består av












og

15 **9.** Fremgangsmåten ifølge et hvilket som helst av kravene 1-6, hvori m er 0.




10. Fremgangsmåten ifølge krav 1, hvori forbindelsen med formel I velges fra gruppen som består av:

20





25




3




5









10









15




















5






























10



15



5












5

10

15









6



























5

10

15







5

10


15




,




,




,




,




,




,



,




,




,


5




,




,




,



,




,




,


10




,




,




,




,




,




,



,






























,



,



15





5

10




15





5



























10















15












12









5






























10



15



14





5



10

15




15





5















10












15












5







10





15






5












10















15




















5






























10















15























5































10












15


















26



eller et dermatologisk akseptabelt salt derav.

11. Fremgangsmåten ifølge et hvilket som helst av kravene 1-10, hvori forbedringen i estetisk utseende er forbedring i én eller flere av hudfarge, utstråling, klarhet, spenstighet, hudens fasthet, plumpeevne, smidighet, mykhet, hudstruktur, hudteksturering og -fuktighet, utseendet til hudkonturer, utseendet til hule kinn, synlighet av innsunkne, posete eller mørke ringer under øynene, hudglans, lyshet, hudtykkelse og hudelastisitet og/eller hudelastisitet.

12. Fremgangsmåten ifølge et hvilket som helst av kravene 1-10, hvori forbedringen i estetisk utseende er reduksjon og/eller forebygging av fine linjer eller rynker.

13. Fremgangsmåten ifølge et hvilket som helst av kravene 1-10, hvori forbedringen i estetisk utseende er reduksjon og/eller forebygging av hudmisfarging.

14. Fremgangsmåten ifølge et hvilket som helst av kravene 1-10, hvori forbindelsen administreres som en kosmetisk sammensetning.

15. Fremgangsmåten ifølge krav 14, hvori den kosmetiske sammensetningen er en topisk sammensetning.